Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Published:2019-03-28 Issue:14 Volume:125 Page:2474-2487
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop M.¹^ORCID,DeAngelo Daniel J.²,Stelljes Matthias³,Liedtke Michaela⁴,Stock Wendy⁵,Gökbuget Nicola⁶,O’Brien Susan M.⁷,Jabbour Elias¹^ORCID,Wang Tao⁸,Liang White Jane⁸,Sleight Barbara⁸,Vandendries Erik⁹,Advani Anjali S.¹⁰

Affiliation:

1. The University of Texas MD Anderson Cancer Center Houston Texas

2. Dana‐Farber Cancer Institute Boston Massachusetts

3. University Hospital Münster Münster Germany

4. Stanford Cancer Institute Stanford California

5. University of Chicago Chicago Illinois

6. Goethe University Frankfurt Germany

7. Irvine Medical Center University of California Orange California

8. Pfizer Inc Groton Connecticut

9. Pfizer Inc Cambridge Massachusetts

10. Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32116

Reference22 articles.

1. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

2. Outcome of adults with acute lymphocytic leukemia after second salvage therapy

3. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

4. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

5. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin;Blood Cancer Journal;2024-08-07

3. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

4. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

5. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3